The findings were robust across several subgroup analyses.
The primary outcome was defined as the first moderate or severe COPD exacerbation, and the primary safety outcome was first pneumonia hospitalization.Īccording to the results, LAMA-LABA use was associated with an 8% reduction in the rate of first moderate or severe COPD exacerbation compared with ICS-LABA use (HR=0.92 95% CI, 0.89-0.96), as well as a 20% reduction in the rate of pneumonia hospitalization (HR=0.80 95% CI, 0.75-0.86). Kesselheim, assessed 30,216 matched pairs of COPD patients who had a filled out a new prescription of ICS-LABAs or LAMA-LABAs between January 1, 2014, and December 31, 2019.
#LAMA LABA FOR COPD TRIAL#
The findings appeared this week in JAMA Internal Medicine.ĬOPD guidelines recommend LAMA-LABAs over ISC-LABAs however, clinical trial data, as the researchers noted, “have been conflicting and raised concerns of generalizability.” A new study suggests that patients with chronic obstructive pulmonary disease (COPD) should be treated with an inhaler combination containing long-acting muscarinic antagonists (LAMAs) and long-acting β-agonists (LABAs) instead of inhalers containing inhaled corticosteroids (ICSs) and LABAs.
0 kommentar(er)
